ViroMissile Clears First Dose Cohort in Phase I Cancer Virus Trial
An independent safety panel has authorized ViroMissile to escalate dosing in its first-in-human trial of intravenous oncolytic virus therapy IDOV-2.
ViroMissile, Inc. announced Wednesday that its Safety Review Committee has cleared the company to advance to a higher dose level in the first-in-human Phase I trial of IDOV-2, an intravenously deliverable oncolytic virus being tested in patients with advanced solid tumors.
The San Diego-based cancer immunotherapy company said the independent committee reviewed safety data from the completed first dose cohort before authorizing progression to the next, higher dose cohort under trial identifier NCT06910657. No adverse safety signals sufficient to halt advancement were disclosed.
Read more RedHammer Partner Joins Intuit Advisory Board for Construction Software →
IDOV-2, previously known as IDOV-Immune, is built on ViroMissile's proprietary IDOV platform, which the company describes as pioneering technology designed to deliver oncolytic viruses directly through the bloodstream rather than via local injection — a distinction the company says broadens the potential reach of such therapies to tumors that are difficult to access surgically.
The trial is being conducted at sites in both the United States and Australia, with the Australian arm operated through the company's subsidiary, ViroMissile Australia, PTY, LTD. Dual-country enrollment in early-phase oncology studies is a common strategy for accelerating patient accrual and satisfying regulatory requirements across multiple jurisdictions.
Dose-escalation trials like this one are designed primarily to establish safety and determine a recommended dose for later-stage testing, not to measure efficacy. Advancement to the next cohort marks a procedural but meaningful milestone in that process. Continue reading at GlobeNewswire - Industry News on Financial Services.
